It is hoped that these transporters can replace the activity of the cystic fibrosis transmembrane conductance anion channel which is missing or dysfunctional in CF sufferers.

In collaboration with Professor David Sheppard​ of the School Physiology, Pharmacology and Neuroscience, the work will involve tests in human cells to validate the concept and prepare the way for clinical translation and commercialisation.